Detalles de la búsqueda
1.
Teplizumab and ß-Cell Function in Newly Diagnosed Type 1 Diabetes.
N Engl J Med;
389(23): 2151-2161, 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861217
2.
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Circulation;
145(8): 565-574, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34775781
3.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Diabetes Obes Metab;
25(8): 2084-2095, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37013892
4.
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Diabetes Obes Metab;
24(6): 1159-1165, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35257461
5.
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Diabetes Obes Metab;
24(1): 34-41, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34617398
6.
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Diabetes Obes Metab;
24(11): 2182-2191, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762489
7.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Diabetes Obes Metab;
24(8): 1522-1533, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35441412
8.
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
Pediatr Diabetes;
23(6): 641-648, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411611
9.
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Diabetes Obes Metab;
23(6): 1331-1341, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565209
10.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Diabetes Obes Metab;
22 Suppl 4: 14-23, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32291880
11.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Diabetes Obes Metab;
22 Suppl 4: 3-13, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072742
12.
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
Diabetes Obes Metab;
22(10): 1880-1885, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515543
13.
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.
Diabetes Obes Metab;
22(4): 612-621, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31797549
14.
Impact of disease duration and ß-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Diabetes Obes Metab;
22(9): 1567-1576, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323437
15.
Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Diabetes Obes Metab;
20(2): 335-343, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28742225
16.
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Diabetes Obes Metab;
19(12): 1798-1804, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432746
17.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Diabetes Obes Metab;
19(10): 1408-1415, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28386990
18.
Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
Diabetes Metab Res Rev;
31(2): 204-11, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25115916
19.
Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Diabetes Metab Res Rev;
30(8): 726-35, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24639432
20.
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Diabetes Care;
45(7): 1592-1600, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35671039